3-methyl-3H-spiro[[2]benzofuran-1,4'-piperidine] | 747353-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异香豆素
• 英文名称: 3-methyl-3H-spiro[[2]benzofuran-1,4'-piperidine]
• 英文别名: 3-methyl-1'H,3H-spiro[2-benzofuran-1,4'-piperidine]；(RS)-3-methyl-3H-spiro[2-benzofuran-1,4'-piperidine]；3-Methyl-3h-spiro[2-benzofuran-1,4'-piperidine]；1-methylspiro[1H-2-benzofuran-3,4'-piperidine]
• CAS: 747353-15-7
• 化学式: C₁₃H₁₇NO
• 分子量: 203.284
• InChiKey: OYKUKNSVTVVZNM-UHFFFAOYSA-N

物化性质

• 沸点：
  336℃
• 密度：
  1.11
• 闪点：
  134℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-3H-spiro[[2]benzofuran-1,4'-piperidine] 、 1-bromo-8-chloro-4H,6H-2,3,5,10b-tetraazabenzo[e]azulene-5-carboxylic acid tert-butyl ester 反应 3.0h， 以36%的产率得到tert-butyl 8-chloro-1-(3-methyl-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-5(6H)-carboxylate
  参考文献：
  名称：

  SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES

  摘要：

  本发明涉及螺环二氢四氮杂苯并吖唑烯，即式I的螺-5,6-二氢-4H-2,3,5,10b-四氮杂苯并[ e ]吖唑烯，其中R1、R2、R3、X、Y、Z、m和n如本文所述。根据本发明的化合物作为V1a受体调节剂，并且在痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、抗利尿素分泌异常、肝硬化、肾病综合征、焦虑、抑郁症、强迫性障碍、自闭症谱系障碍、精神分裂症和攻击性行为等病症中作用于外周和中枢方面，具有治疗用途。

  公开号：

  US20100120751A1
• 作为产物：
  描述：

  1'-benzyl-3-(fluoromethyl)-3H-spiro[[2]benzofuran-1,4'-piperidine] 在 甲醇 、 palladium 10% on activated carbon 、 甲酸铵 作用下， 反应 3.0h， 生成 3-methyl-3H-spiro[[2]benzofuran-1,4'-piperidine] 、 3-(fluoromethyl)-3H-spiro[[2]benzofuran-1,4'-piperidine]
  参考文献：
  名称：

  Synthesis, radiofluorination and pharmacological evaluation of a fluoromethyl spirocyclic PET tracer for central σ1 receptors and comparison with fluoroalkyl homologs

  摘要：

  The spirocyclicr1 receptor ligand 1 (1'-benzyl-3-(fluoromethyl)-3H-spiro[[2] benzofuran-1,4'-piperidine]) was prepared in four steps starting from methoxy derivative 5. Due to its high sigma(1) affinity (K-i = 0.74 nM) and selectivity against several other relevant targets, 1 was investigated as F-18-labeled PET tracer and its biological properties were compared with those of homologous fluoroalkyl derivatives 2-4. The fluoromethyl derivative 1 was faster metabolized in vitro than homologs 2-4. In contrast to the radiosynthesis of [F-18]2-4, the nucleophilic substitution of the tosylate 15 using the K[F-18]F-K-222-carbonate complex required heating to 150 degrees C in DMSO to achieve high labeling efficiencies. Whereas radiometabolites of [F-18]2-4 were not detected in vivo in the brain of mice, two radiometabolites of [F-18]1 were found. Analysis of ex vivo autoradiography images provided rather low target-to-nontarget ratio for [F-18]1 compared with [F-18]2-4. [F-18]1 showed a fast uptake in the brain, which decreased continuously over time. The brain-to-plasma ratio of the radiotracer [F-18]1 was only exceeded by the fluoroethyl tracer [F-18]2. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.002

文献信息

• Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1<i>H</i>-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors
  作者：Tim Cernak、Nathan J. Gesmundo、Kevin Dykstra、Yang Yu、Zhicai Wu、Zhi-Cai Shi、Petr Vachal、Donald Sperbeck、Shuwen He、Beth Ann Murphy、Lisa Sonatore、Steven Williams、Maria Madeira、Andreas Verras、Maud Reiter、Claire Heechoon Lee、James Cuff、Edward C. Sherer、Jeffrey Kuethe、Stephen Goble、Nicholas Perrotto、Shirly Pinto、Dong-Ming Shen、Ravi Nargund、James Balkovec、Robert J. DeVita、Spencer D. Dreher

  DOI：10.1021/acs.jmedchem.6b01543

  日期：2017.5.11

  Miniaturization and parallel processing play an important role in the evolution of many technologies. We demonstrate the application of miniaturized high-throughput experimentation methods to resolve synthetic chemistry challenges on the frontlines of a lead optimization effort to develop diacylglycerol acyltransferase (DGAT1) inhibitors. Reactions were performed on ∼1 mg scale using glass microvials

  小型化和并行处理在许多技术的发展中起着重要作用。我们展示了微型高通量实验方法的应用，以解决领先的开发二酰基甘油酰基转移酶（DGAT1）抑制剂的最优化工作的前线对合成化学的挑战。使用玻璃微瓶以大约1 mg的规模进行反应，可提供小型化的高通量实验能力，用于研究具有挑战性的S N Ar反应。在这些小型研究中发现的稳健的合成化学条件的可用性使结构-活性关系得以发展，最终导致了可溶性，选择性和有效的DGAT1抑制剂的发现。
• [EN] METHOD FOR MANUFACTURE OF DIHYDROISOBENZOFURAN DERIVATIVES<br/>[FR] PROCEDE DE PREPARATION DE DERIVES DE DIHYDROISOBENZOFURANNE
  申请人：LUNDBECK & CO AS H

  公开号：WO2004026855A1

  公开（公告）日：2004-04-01

  The present invention relates to a method for the manufacture of dihydroisobenzofurans of formula I; comprising generation a dianion of formula II, reaction of the dianion with a carbonyl compound of formula III and acidification of the reaction mixture to generate a diol of formula IV; followed by ring closure of the diol of formula IV to obtain the dihydroisobenzofuran of formula I.

  本发明涉及一种制备式I的二氢异苯并呋喃的方法；包括生成式II的二阴离子，将二阴离子与式III的羰基化合物反应，并酸化反应混合物以生成式IV的二元醇；随后将式IV的二元醇环合以获得式I的二氢异苯并呋喃。
• Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists
  申请人：Hashizume Yoshinobu

  公开号：US20050277659A1

  公开（公告）日：2005-12-15

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 independently represent a hydrogen atom or the like; R 3 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like; and n represents an integer 0, 1 or 2. These compounds have ORL 1 -receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了式（I）的化合物：或其药学上可接受的酯，或其药学上可接受的盐，其中R1和R2分别独立地表示氢原子或类似物；R3表示具有6至10个环原子或类似物的芳基基团；X表示氧原子或类似物；Y表示氧原子或类似物；n表示整数0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们可用于治疗疾病或病症，例如疼痛，各种中枢神经系统疾病等。
• Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonists
  申请人：Hashizume Yoshinobu

  公开号：US20070197500A1

  公开（公告）日：2007-08-23

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 independently represent a hydrogen atom or the like; R 3 represents a hydrogen atom, or the like; R 4 represents a hydrogen atom or the like; (formula II) represents one of the following or the like; R 5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了以下化合物的公式(I)、其药学上可接受的酯或其药学上可接受的盐，其中R1和R2独立地表示氢原子或类似物；R3表示氢原子或类似物；R4表示氢原子或类似物；(公式II)代表以下之一或类似物；R5表示具有6至10个环原子的芳基基团或类似物；X表示氧原子或类似物；Y表示氧原子或类似物，n表示整数0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们对于治疗疾病或症状，如疼痛、各种中枢神经系统疾病等非常有用。
• Novel Piperidine Derivative
  申请人：Ishikawa Shiho

  公开号：US20090137576A1

  公开（公告）日：2009-05-28

  Disclosed is a substance having an antagonistic effect on the binding of histamine to a histamine H3 receptor or an inhibitory effect on the activity which a histamine H3 receptor constantly exhibits. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 represents a phenyl group which may be substituted or the like and R2 represents a cyano group which may be substituted or the like, or R1 and R2 together form an aliphatic heterocylic ring which may be substituted; R3 represents a group represented by the formula (II-1) below; and all of X1 to X4 represent a carbon atom or the like: (II-1) where R4 and R5 represent a lower alkyl group or the like; and m1 represents an integer of 2 to 4.

  本发明涉及一种物质，其对组胺与组胺H3受体的结合具有拮抗作用，或对组胺H3受体不断表现的活性具有抑制作用。化合物由式(I)或其药学上可接受的盐表示；(I)其中R1代表可能被取代或类似的苯基团，R2代表可能被取代或类似的氰基团，或R1和R2一起形成可能被取代的脂肪族杂环环；R3代表由下式(II-1)表示的基团；X1到X4都表示碳原子或类似物：(II-1)其中R4和R5代表较低的烷基团或类似物；m1表示2到4的整数。